Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 7713 participants.

Also called NCT06930885

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 7,713 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT06930885
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Brazil (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT06930885. Randomized; quadruple masking; primary purpose treatment. Start 2025-06-12 (actual); primary completion 2031-05 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Polypill and Colchicine for Risk Reduction in Atherosclerotic Cardiovascular Disease
Acronym
EPOCA
Condition
Atherothrombotic Diseases
Condition
Atherosclerotic Cardiovascular Disease (ASCVD)
Intervention (Drug)
Cardiovascular Polypill (Valsartan, Atorvastatin, Aspirin)
Intervention (Drug)
Colchicine 0.5 mg
Intervention (Drug)
Usual Care Group
Intervention (Drug)
Colchicine-placebo 0.5 mg
Lead sponsor
Hospital do Coracao (class: other)

Record details

Record id
cardio:ct-nct06930885
Content hash
ff81930827baa28d5eb4f8bacfc3985ce73f8f82a8ccecd0f7c82960ae4be1c3